🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

19+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

ℹ
Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 19 of 19 recruiting trials for “Chronic myeloid leukemia”

Enrolling by InvitationNCT07383298 ↗

Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase

👨‍⚕️ Qian Jiang, Dr., Peking University People's Hospital📍 1 site📅 Started Dec 2025View details ↗
Phase 2RecruitingNCT06817720 ↗

Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

👨‍⚕️ Fadi Haddad, MD, M.D. Anderson Cancer Center📍 1 site📅 Started Oct 2025View details ↗
RecruitingNCT07061145 ↗

A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid Leukemia

👨‍⚕️ Isabella Capodanno, MD, Azienda USL - IRCCS di Reggio Emilia📍 1 site📅 Started Jul 2025View details ↗
Phase 1RecruitingNCT06787144 ↗

ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants

👨‍⚕️ Helen Collins, MD, Enliven Therapeutics📍 4 sites📅 Started Jan 2025View details ↗
RecruitingNCT06665412 ↗

Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML

👨‍⚕️ Na Yun Kim, Il-Yang Pharm. Co., Ltd.📍 2 sites📅 Started Oct 2024View details ↗
Phase 2RecruitingNCT06236724 ↗

Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

👨‍⚕️ Elias Jabbour, MD, M.D. Anderson Cancer Center📍 1 site📅 Started Jan 2024View details ↗
Phase 3RecruitingNCT05753384 ↗

Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System

🏥 Poitiers University Hospital📍 20 sites📅 Started Dec 2023View details ↗
RecruitingNCT06119269 ↗

Ponatinib in Chronic Myeloid Leukemia Patients in Chronic Phase

👨‍⚕️ Sara Galimberti, PhD, University of Pisa - Dept. Clinical and Experimental Medicine📍 5 sites📅 Started Aug 2023View details ↗
RecruitingNCT05943522 ↗

Asciminib RMP Study

👨‍⚕️ Novartis Pharmaceuticals, Novartis Pharmaceuticals📍 14 sites📅 Started Jul 2023View details ↗
Phase 4RecruitingNCT04877522 ↗

Asciminib Roll-over Study

👨‍⚕️ Novartis Pharmaceuticals, Novartis Pharmaceuticals📍 84 sites📅 Started Aug 2022View details ↗
RecruitingNCT05439889 ↗

Follow-up Study on Chronic Myeloid Leukemia Patients Achieving Treatment-free Remission

🏥 National Taiwan University Hospital📍 1 site📅 Started Aug 2022View details ↗
Phase 2RecruitingNCT04838041 ↗

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

👨‍⚕️ Ehab Atallah, MD, Medical College of Wisconsin📍 4 sites📅 Started Nov 2021View details ↗
Phase 1RecruitingNCT03326310 ↗

Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

👨‍⚕️ Olatoyosi Odenike, MD, University of Chicago📍 1 site📅 Started Sep 2018View details ↗
Phase 3RecruitingNCT03459534 ↗

A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs

👨‍⚕️ Dong Wook Kim, the Catholic University of Korea's St. Mary's Hospital📍 18 sites📅 Started Jun 2018View details ↗
NARecruitingNCT03481868 ↗

EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors

👨‍⚕️ Marc BERGER, University Hospital, Clermont-Ferrand📍 16 sites📅 Started Feb 2018View details ↗
RecruitingNCT05963061 ↗

Chronic Myeloid Leukemia (CML) Real-Life Database

👨‍⚕️ Marc BERGER, MD, University Hospital, Clermont-Ferrand📍 14 sites📅 Started Apr 2014View details ↗
Phase 2RecruitingNCT01746836 ↗

Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

👨‍⚕️ Elias Jabbour, MD, M.D. Anderson Cancer Center📍 1 site📅 Started Jan 2013View details ↗
RecruitingNCT01281735 ↗

International Chronic Myeloid Leukemia Pediatric Study

👨‍⚕️ Frederic MILLOT, MD, Poitiers University Hospital📍 20 sites📅 Started Jan 2011View details ↗
RecruitingNCT00816114 ↗

Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial

👨‍⚕️ Koji Sasaki, M.D., M.D. Anderson Cancer Center📍 1 site📅 Started Jun 2005View details ↗

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →